Compare ASTRAZENECA PHARMA with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs WYETH LTD - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA WYETH LTD ASTRAZENECA PHARMA/
WYETH LTD
 
P/E (TTM) x 81.8 27.7 295.0% View Chart
P/BV x 23.0 5.3 430.7% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ASTRAZENECA PHARMA   WYETH LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
WYETH LTD
Mar-13
ASTRAZENECA PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,2781,044 122.4%   
Low Rs883818 107.9%   
Sales per share (Unadj.) Rs228.4298.6 76.5%  
Earnings per share (Unadj.) Rs10.457.2 18.1%  
Cash flow per share (Unadj.) Rs16.358.4 27.8%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs98.8249.5 39.6%  
Shares outstanding (eoy) m25.0022.72 110.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.1 151.7%   
Avg P/E ratio x104.216.3 640.7%  
P/CF ratio (eoy) x66.415.9 416.8%  
Price / Book Value ratio x10.93.7 293.0%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m27,00821,157 127.7%   
No. of employees `0001.40.5 275.6%   
Total wages/salary Rs m1,535400 383.8%   
Avg. sales/employee Rs Th4,210.913,787.4 30.5%   
Avg. wages/employee Rs Th1,132.2813.0 139.3%   
Avg. net profit/employee Rs Th191.12,643.3 7.2%   
INCOME DATA
Net Sales Rs m5,7106,783 84.2%  
Other income Rs m123353 34.7%   
Total revenues Rs m5,8337,136 81.7%   
Gross profit Rs m4631,617 28.6%  
Depreciation Rs m14727 554.1%   
Interest Rs m06 0.0%   
Profit before tax Rs m4381,938 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m179632 28.3%   
Profit after tax Rs m2591,301 19.9%  
Gross profit margin %8.123.8 34.0%  
Effective tax rate %40.832.6 125.2%   
Net profit margin %4.519.2 23.7%  
BALANCE SHEET DATA
Current assets Rs m3,2096,984 46.0%   
Current liabilities Rs m2,0702,056 100.7%   
Net working cap to sales %20.072.6 27.5%  
Current ratio x1.63.4 45.6%  
Inventory Days Days7299 72.9%  
Debtors Days Days3524 145.9%  
Net fixed assets Rs m790244 323.5%   
Share capital Rs m50227 22.0%   
"Free" reserves Rs m2,4195,441 44.5%   
Net worth Rs m2,4695,668 43.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,6057,901 58.3%  
Interest coverage xNM353.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.9 144.4%   
Return on assets %5.616.5 34.0%  
Return on equity %10.522.9 45.7%  
Return on capital %17.734.0 52.1%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m30015 1,970.7%   
Fx outflow Rs m2,0152,677 75.3%   
Net fx Rs m-1,715-2,662 64.4%   
CASH FLOW
From Operations Rs m88923 9.5%  
From Investments Rs m-94317 -29.5%  
From Financial Activity Rs mNA-481 0.0%  
Net Cashflow Rs m-6759 -0.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.1 146.8%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 7.2 218.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 30.4 29.9%  
Shareholders   12,856 21,978 58.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  ALEMBIC LTD  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS